CN112513079A - 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体 - Google Patents

用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体 Download PDF

Info

Publication number
CN112513079A
CN112513079A CN201980018712.7A CN201980018712A CN112513079A CN 112513079 A CN112513079 A CN 112513079A CN 201980018712 A CN201980018712 A CN 201980018712A CN 112513079 A CN112513079 A CN 112513079A
Authority
CN
China
Prior art keywords
cancer
cells
cxcr4
cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980018712.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·维拉昆卡
P·冈萨雷斯纳瓦罗
J·瓦伦丁基罗加
A·埃斯库德罗洛佩兹
L·费尔南德斯卡萨诺娃
A·佩雷斯马丁内斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carlos Iii Cancer Research Center Public Asset Foundation
Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz
Original Assignee
Carlos Iii Cancer Research Center Public Asset Foundation
Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlos Iii Cancer Research Center Public Asset Foundation, Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz filed Critical Carlos Iii Cancer Research Center Public Asset Foundation
Publication of CN112513079A publication Critical patent/CN112513079A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4219—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201980018712.7A 2018-03-13 2019-03-13 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体 Pending CN112513079A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642313P 2018-03-13 2018-03-13
US62/642,313 2018-03-13
PCT/IB2019/052042 WO2019175802A1 (en) 2018-03-13 2019-03-13 Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy

Publications (1)

Publication Number Publication Date
CN112513079A true CN112513079A (zh) 2021-03-16

Family

ID=66286540

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018712.7A Pending CN112513079A (zh) 2018-03-13 2019-03-13 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体

Country Status (7)

Country Link
US (1) US20230181635A1 (https=)
EP (1) EP3765519B1 (https=)
JP (2) JP7561631B2 (https=)
KR (1) KR102693317B1 (https=)
CN (1) CN112513079A (https=)
ES (1) ES2973728T3 (https=)
WO (1) WO2019175802A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117715647A (zh) * 2021-04-08 2024-03-15 埃迪瓦生物治疗公司 用nk细胞和cd38靶向抗体治疗癌症

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN115836666B (zh) * 2021-09-20 2024-11-01 上海中医药大学附属龙华医院 原位骨肉瘤和肺转移瘤小鼠模型及其制法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528259A (zh) * 2006-10-02 2009-09-09 米德列斯公司 结合cxcr4的人类抗体及其用途
CN102428173A (zh) * 2009-03-26 2012-04-25 阿瓦里斯有限责任公司 Nk细胞的扩增
CN103649120A (zh) * 2011-06-20 2014-03-19 皮埃尔法布雷医药公司 具有效应功能的抗cxcr4抗体及其用于治疗癌症的用途
CN104039320A (zh) * 2011-11-09 2014-09-10 百时美施贵宝公司 血液恶性肿瘤用抗-cxcr4抗体的治疗
CN106211774A (zh) * 2013-08-02 2016-12-07 辉瑞公司 抗cxcr4抗体及抗体‑药物缀合物
WO2017049228A1 (en) * 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Modified natural killer cells having anti-fugetactic properties and uses thereof
US20170334993A1 (en) * 2014-10-28 2017-11-23 University Children's Hospital Tübingen Treatment of pediatric bcp-all patients with an anti-kir antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532399T3 (es) 2003-03-05 2015-03-26 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EA201071300A1 (ru) 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
WO2013013025A2 (en) 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
EP3066129B1 (en) 2013-11-06 2019-06-19 Bristol-Myers Squibb Company Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
EP3307778A1 (en) 2015-06-12 2018-04-18 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528259A (zh) * 2006-10-02 2009-09-09 米德列斯公司 结合cxcr4的人类抗体及其用途
CN102428173A (zh) * 2009-03-26 2012-04-25 阿瓦里斯有限责任公司 Nk细胞的扩增
CN103649120A (zh) * 2011-06-20 2014-03-19 皮埃尔法布雷医药公司 具有效应功能的抗cxcr4抗体及其用于治疗癌症的用途
CN104039320A (zh) * 2011-11-09 2014-09-10 百时美施贵宝公司 血液恶性肿瘤用抗-cxcr4抗体的治疗
CN106211774A (zh) * 2013-08-02 2016-12-07 辉瑞公司 抗cxcr4抗体及抗体‑药物缀合物
US20170334993A1 (en) * 2014-10-28 2017-11-23 University Children's Hospital Tübingen Treatment of pediatric bcp-all patients with an anti-kir antibody
WO2017049228A1 (en) * 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Modified natural killer cells having anti-fugetactic properties and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117715647A (zh) * 2021-04-08 2024-03-15 埃迪瓦生物治疗公司 用nk细胞和cd38靶向抗体治疗癌症

Also Published As

Publication number Publication date
KR20200132915A (ko) 2020-11-25
US20230181635A1 (en) 2023-06-15
EP3765519B1 (en) 2024-01-17
ES2973728T3 (es) 2024-06-24
JP2024105305A (ja) 2024-08-06
WO2019175802A9 (en) 2019-12-12
WO2019175802A1 (en) 2019-09-19
JP2021517588A (ja) 2021-07-26
JP7561631B2 (ja) 2024-10-04
KR102693317B1 (ko) 2024-08-07
EP3765519A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
JP7021153B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン－４ｄ阻害分子の使用
KR102812377B1 (ko) 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
US20210301020A1 (en) Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
AU2018243020A1 (en) Medicinal composition for treating cancer
TW201806619A (zh) 嵌合抗原受體及pd-1抑制劑之組合療法
CN118852450A (zh) 双特异性抗体组合物及其使用方法
HK1252272A1 (zh) 使用抗ox40抗体治疗癌症的方法
WO2017037707A1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
KR20230119265A (ko) 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1항체의 용도
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
JP2024105305A (ja) 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体
US12187792B2 (en) IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
US20230192803A1 (en) Anti-steap2 chimeric antigen receptors and uses thereof
Kim et al. Chimeric antigen receptor t cells with modified interleukin-13 preferentially recognize IL13Rα2 and suppress malignant glioma: a preclinical study
Martins et al. EphA3 CAR T cells are effective against glioblastoma in preclinical models
Osorio et al. Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer
US20240374644A1 (en) Herv-k antibody therapeutics
JP2022528238A (ja) がん療法で使用するためのセマフォリン－４ｄアンタゴニスト
JP7148151B2 (ja) 抗レナラーゼ抗体および抗ｐｄ－１抗体を用いる、がんを処置するための組成物および方法
TWI790193B (zh) 調控免疫反應之方法及抗體
RU2827900C1 (ru) Kir3dl3 - ингибирующий рецептор иммунной системы и его применение
KR20250116736A (ko) Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법
WO2023150260A2 (en) Compounds that target tem8, compositions, and methods
KR20250005988A (ko) Kir3dl3 억제제 및 면역 세포 활성화제
Arenas-Ramirez Immunotherapy Using a Novel Agonistic Anti-IL-2 Antibody Combined with Epigenetic Modulation Limits Tumor Immune Escape and Controls Tumor Growth

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination